血清游离免疫球蛋白轻链与华氏巨球蛋白血症中的肿瘤负荷标志物相关。
Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
作者信息
Leleu Xavier, Moreau Anne-Sophie, Weller Edie, Roccaro Aldo M, Coiteux ValéRie, Manning Robert, Nelson Marybeth, Leduc Renee, Robu Daniela, Dupire Sophie, Hatjiharissi Evdoxia, Burwick Nicholas, Darre Stéphane, Hennache Bernadette, Treon Steven P, Facon Thierry, Gertz Morie A, Ghobrial Irene M
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School Boston, MA 02115, USA.
出版信息
Leuk Lymphoma. 2008 Jun;49(6):1104-7. doi: 10.1080/10428190802074619.
The serum IgM level has been utilised as a marker of tumor progression and to assess response to therapy in patients with Waldenstrom macroglobulinemia (WM). However, there are many limitations to the IgM protein level. The objective of this study was to evaluate the association of known tumor burden markers and prognostic factors with serum free light chain (sFLC) in 98 patients with WM. We demonstrated that sFLC measurement accurately differentiated IgM-MGUS compared with WM reflecting a measurement of tumor burden. In univariate and multivariate analysis, median sFLC at the cut-off at 60 mg/L was higher for WM patients with low hemoglobin and high beta2M, when we applied the WM-IPSS cut-offs, but showed no association with IgM level. This study demonstrates that sFLC is a new marker in WM disease. Further analysis is required to prospectively study the role of sFLC in monitoring response to therapy and as a prognostic marker in WM patients.
血清IgM水平已被用作肿瘤进展的标志物，并用于评估华氏巨球蛋白血症（WM）患者对治疗的反应。然而，IgM蛋白水平存在许多局限性。本研究的目的是评估98例WM患者中已知的肿瘤负荷标志物和预后因素与血清游离轻链（sFLC）的相关性。我们证明，与反映肿瘤负荷测量的WM相比，sFLC测量能准确区分IgM意义未明的单克隆丙种球蛋白血症（IgM-MGUS）。在单变量和多变量分析中，当我们应用WM国际预后评分系统（WM-IPSS）的临界值时，血红蛋白低和β2微球蛋白（beta2M）高的WM患者在临界值为60 mg/L时的sFLC中位数较高，但与IgM水平无关。本研究表明，sFLC是WM疾病中的一种新标志物。需要进一步分析以前瞻性研究sFLC在监测治疗反应中的作用以及作为WM患者预后标志物的作用。
Zotero 插件